Application of Omic Techniques to Identify New Biomarkers and Drug Targets for COVID-19 (eBook)
XI, 513 Seiten
Springer-Verlag
978-3-031-28012-2 (ISBN)
The COVID-19 pandemic caused by the SARS-CoV-2 virus has affected nearly every country and territory in the world. Although worldwide vaccination efforts have reduced the risk of serious disease outcomes, disparities in distribution have led to multiple waves of SARS-CoV-2 outbreaks and the emergence of variants of concern, some of which have enhanced infectivity and ability to evade existing vaccines. Hence there is an increasing interest in understanding the evolution of viruses like SARS-CoV-2, as well as improving our capacity to effectively current and manage future pandemics.
This new volume reviews the most effective omic techniques for increasing our understanding of COVID-19, to improve diagnostics, prognostics, and genomic surveillance, and to facilitate development of effective treatments and vaccines. Chapters are written by an international team of experts and explore methods in the areas of genomics, transcriptomics, proteomics, and metabolomics. Techniques used to assess physiological function at the molecular level and artificial intelligence approaches used for more effective validation and translation of biomarker candidates into clinical use are also discussed. This book is an excellent resource for researchers studying biomarkers, virology, metabolic diseases, and infectious diseases, as well as clinical scientists, physicians, drug company scientists, and healthcare workers.
Dr. Paul C. Guest, Ph.D, is a scientific researcher/writer with 38 years of experience in the fields of metabolic and neurological disorders. This includes experience in both academia and the pharmaceutical industry with the majority of time spent at the University of Cambridge and Merck Sharp & Dohme in the United Kingdom. He is also affiliated with the University of Campinas in Sao Paulo Brazil and Otto-von-Guericke-University in Magdeburg Germany, still focused on advancing the field of biomarkers for neurological disorders such as schizophrenia, age-related diseases such as diabetes, cancer, cardiovascular disorders, sarcopenia and Alzheimer's disease, and more recently on infectious diseases such as COVID-19.
Erscheint lt. Verlag | 28.6.2023 |
---|---|
Reihe/Serie | Advances in Experimental Medicine and Biology | Proteomics, Metabolomics, Interactomics and Systems Biology |
Zusatzinfo | XI, 513 p. 87 illus., 74 illus. in color. |
Sprache | englisch |
Themenwelt | Medizin / Pharmazie ► Studium |
Naturwissenschaften ► Biologie | |
Naturwissenschaften ► Chemie | |
Schlagworte | Biomarkers • Covid-19 • Drug targets • genomics • Metabolomics • Omic Techniques • Proteomics |
ISBN-10 | 3-031-28012-1 / 3031280121 |
ISBN-13 | 978-3-031-28012-2 / 9783031280122 |
Haben Sie eine Frage zum Produkt? |
Größe: 23,3 MB
DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasserzeichen und ist damit für Sie personalisiert. Bei einer missbräuchlichen Weitergabe des eBooks an Dritte ist eine Rückverfolgung an die Quelle möglich.
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich